A new space to produce highly potent APIs
Olon Group is pleased to announce the next strategic development milestone of Olon Ricerca Bioscience, the campus located in Ohio (US), mostly focused on R&D. The latest investments for Olon Ricerca Bioscience (ORB) are to set up a new line to produce highly potent APIs (HPAPIs).
So Olon, that has years of expertise in HPAPIs, makes ORB be aligned with that technology, to bring on clients that need HPAPIs in clinical phases, as early as possible. In the near future the company could offer HPAPIs for early clinical phases and then transfer programs to the European sites for later-phase clinical and beyond.
ORB campus has officially begun the investment in HPAPI capabilities. Over the long term, the plan is to increase its capacity to meet demand up to a hundred grams and bring U.S. site to mirror the capacity of the Italian facilities, which includes multiple sites that can perform the production of HPAPIs on a larger scale.
ORB has also expanded its capacity, closing the gap between preclinical phase and commercial production, where it already played, adding on capabilities for the initial development of new chemical entities (NCEs).
“Now, we can take clients from pre-clinical to phase II and then, if the project is successful, transfer the technology to our European sites for phase III/commercial. We offer our customers a full partnership from preclinical up to commercial. Although we don’t carry out production from start to finish of the API development at the same site, our customers appreciate the fact that their program can be completed through a single provider. Up to know we have already several examples demonstrating the smooth technological transfer of processes and analytics between the two side of the oceans within the same quality and operational system” commented Luigi Trussardo, CEO of Olon Ricerca Bioscience.